natgillin/translations-raw huggingface dataset:
For immunisation of horses against Streptococcus equi to reduce clinical signs and occurrence of lymph node abscesses.
Imunizacija konjev proti Streptococcusu equi za zmanjšanje kliničnih znakov in nastanka abscesov limfnih vozlov
Read the package insert before use.
Po rekonstituciji 0, 2 ml submukozno na notranjo stran zgornje ustnice Pred uporabo preberite navodilo za uporabo.
EXP solvent {month/ year} EXP vaccine {month/ year}
EXP vehikel {mesec/ leto} EXP cepivo {mesec/ leto}
Reconstituted vials should be used within 4 hours.
Viale z rekonstituiranim cepivom uporabite v 4 urah.
< batch > {number}
< serija > {številka}
12/ 23 PARTICULARS TO APPEAR ON THE INNER BOX WITH VACCINE
PRIMARNI OVOJNINI S CEPIVOM
For immunisation against Streptococcus equi
Imunizacija proti Streptococcusu equi
For submucosal injection after reconstitution
Za submukozno injiciranje po rekonstituciji
Exp {month/ year}
EXP{ mesec/ leto}
14/ 23 PARTICULARS TO APPEAR ON THE INNER BOX WITH SOLVENT
PRIMARNI OVOJNINI Z VEHIKLOM
< lot > {number}
< lot > {številka}
16/ 23 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
16/ 23 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Label of the vaccine (small vial)
Nalepka na cepivu (mala viala)
ROUTE OF ADMINISTRATION
POT UPORABE ZDRAVILA
For submucosal use.
Za submukozno uporabo.
< Batch > {number}
< Serija > {številka}
17/ 23 Label of the solvent (small vial)
17/ 23 Nalepka na vehiklu (mala viala)
See package insert.
Glejte priloženo navodilo.
Exp {month/ year}
Exp {mesec/ leto}
19/ 23 PACKAGE LEAFLET
19/ 23 NAVODILO ZA UPORABO
6 ADVERSE REACTIONS
NEŽELENI UČINKI
1 Colony forming units
_____________________________________ 1 Colony forming units – kolonijske enote
20/ 23 Slight enlargements, which may be transient painful, of the retropharyngeal and mandibular lymph nodes may occur for a few days after vaccination.
20/ 23 Nekaj dni po cepljenju so lahko blago povečani retrofaringealni in mandibularni limfni vozli, kar lahko spremlja prehodna bolečina.
In rare cases, inappetance, fever and shivering may be observed.
Redko lahko zasledimo anoreksijo, vročino in tresenje.
7 TARGET SPECIES
CILJNE ŽIVALSKE VRSTE
Submucosal vaccination of 0.2 ml of reconstituted product.
Submukozno cepljenje z 0, 2 ml rekonstituiranega cepiva
Horses from 4 months of age onwards receive two vaccinations of one dose with a 4 week interval.
Konje po 4. mesecu starosti cepimo dvakrat s po enim odmerkom cepiva v razmaku 4 tednov.
9 ADVICE ON CORRECT ADMINISTRATION
NASVET O PRAVILNI UPORABI ZRAVILA
Aseptically reconstitute the freeze-dried vaccine with 0.3 ml of the sterile solvent provided.
Aseptično rekonstituirajte liofilizirano cepivo z 0, 3 ml priloženega sterilnega vehikla.
Withdraw 0.2 ml of the reconstituted vaccine into the syringe provided with the vaccine (see Figure 1) and connect the applicator to the needle (see Figure 2).
S priloženo brizgo odvzemite 0, 2 ml rekonstituiranega cepiva (glejte sliko 1) in na iglo namestite aplikator (glejte sliko 2).
21/ 23 Figure 2
21/ 23 Slika 2
Reconstituted vials should be used within 4 hours.
Rekonstituirano cepivo je treba uporabiti v 4 urah.
The vaccine strain is sensitive to penicillins, tetracyclins, macrolides and lincomycin.
Cepni sev je občutljiv za peniciline, tetracikline, makrolide in linkomicin.
Ensure that the lyophilisate is completely reconstituted before use.
Pred uporabo preverite, ali je liofilizirani prašek povsem rekonstituiran.
22/ 23 Special precautions to be taken by the person administering the veterinary medicinal product to animals
22/ 23 Posebni varnostni ukrepi, ki jih mora upoštevati oseba, ki živalim daje zdravilo
In case of accidental self injection, seek medical advice immediately and show the package insert or the label to the physician
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
Accidental self injection may result in an inflammatory reaction with severe pain and swelling.
Nenamerno samo- injiciranje lahko povzroči vnetno reakcijo s hudo bolečino in oteklino.
Limited information is available on the safety and efficacy from the use of this vaccine with any other.
Na voljo je malo podatkov o varnosti ter učinkovitosti ob sočasni uporabi tega cepiva s katerim koli drugim cepivom.
Shedding of the vaccine strain from the injection site can be observed for a period of four days after vaccination. From literature, it is known that a very low number of horses may develop purpura haemorrhagica if they are vaccinated shortly after infection.
Iz literature je znano, da se lahko pri zelo majhnem številu konjev razvije hemoragična purpura, če jih cepimo kmalu po okužbi.
For any information about this veterinary medicinal product, please contact the Marketing Authorisation Holder.
Za vse nadaljnje informacije o tem zdravilu se obrnite na krajevno predstavništvo imetnika dovoljenja za promet z zdravilom.
Vaccines work by ‘ teaching’ the immune system (the body’ s natural defences) how to defend itself against diseases.
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „ naučijo “, kako naj se brani proti boleznim.
Page 2/ 3 ©EMEA 2008 Other information about Equilis Te:
Stran 2/ 3 ©EMEA 2008 Druge informacije o zdravilu Equilis Te:
Invented Name
Izmišljeno Jakost ime
Tetanus toxoid ≥ 30 IU/ ml
toksoida tetanusa ≥ 30 i. e. / ml
Vials (Type I glass) closed with a halogenobutyl rubber stopper and aluminium cap.
viale (steklo tipa I), zaprte z zamaški iz halogenobutilne gume in zatesnjene z aluminijastimi zaporkami
Tetanus toxoid ≥ 30 IU/ ml
toksoida
Pre-filled syringes (Type I glass) with a plunger and cap tip of halogenobutyl rubber
napolnjene brizge
1 dose
1
Equilis Te, suspension for injection, for horses
Equilis Te, suspenzija za injiciranje za konje
40 Lf1
40 Lf1 Toksoid tetanusa
Purified Saponin Cholesterol Phosphatidylcholine
Dodatek Prečiščeni saponin Holesterol Fosfatidilholin
of immunity:
Trajanje imunosti:
4.4 Special warnings
4. 4 Posebna opozorila za vsako ciljno živalsko vrsto
Special precautions for use in animals Only healthy animals should be vaccinated.
Posebni previdnostni ukrepi za uporabo pri živalih
1 Flocculation equivalents; corresponds with ≥ 30 IU/ ml guinea pig serum in the Ph.
________________________________ 1 flokulacijski ekvivalenti; ustreza ≥ 30 i. e. / ml seruma budre v preskusu potentnosti v Ph.
Eur. potency test
Eur.
2/ 16 Special precautions to be taken by the person administering the veterinary medicinal product to animals
Posebni varnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Če vam je bil ta izdelek nenamerno injiciran, se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko.
A diffuse hard or soft swelling (max. diameter 5 cm) may occur, regressing within 2 days.
Lahko se pojavi neostro omejena trda ali mehka oteklina (premera največ 5 cm), ki mine v 2 dneh.
In some cases fever may occur for 1 day, and up to 3 days in exceptional circumstances.
V nekaterih primerih se lahko pojavi vročina, ki traja 1 dan, izjemoma 3 dni.
V1 0
C4
V2 1
1
V3 18
18
V4 42 months
42 mesecev
In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later)
Kadar je povečana ogroženost zaradi okužbe ali premajhen vnos kolostruma, lahko pri starosti 4 mesecev damo dodatni odmerek in nato izvedemo poln program cepljenja (osnovno cepljenje pri starosti 6 mesecev in 4 tedne pozneje).
The vaccine can be used together with Tetanus-Serum from Intervet for treatment of injured horses that have not been immunised against tetanus.
Cepivo lahko uporabljamo hkrati z Intervetovim Tetanus- Serumom za zdravljenje konj s poškodbami, ki niso bili imunizirani proti tetanusu.
In that case, the first dose (V1) of vaccine can be given concurrently with the appropriate prophylactic dose of Tetanus-Serum from Intervet at a separate injection site, using separate syringes and needles.
V tem primeru lahko damo prvi odmerek (C1) cepiva sočasno z ustreznim profilaktičnim odmerkom Intervetovega Tetanus- Seruma, na drugo mesto in s posebnimi brizgami in iglami.
This will lead to a passive protection against tetanus for at least 21 days after concurrent administration.
To vzbudi pasivno zaščito pred tetanusom, ki traja najmanj 21 dni po sočasnem
3/ 16 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Drugi odmerek cepiva (C2) moramo dati 4 tedne pozneje.
Following the administration of a double dose of vaccine, no side-effects other than those described under 4.6 have been observed except for some depression at the day of vaccination.
Dvojni odmerek cepiva ni povzročil neželenih učinkov, ki bi se razlikovali od tistih, opisanih v 4. 6, razen blage depresivnosti na dan cepljenja.
To stimulate active immunity against tetanus ATC-vet code:
Za vzbujanje aktivne imunosti proti tetanusu Oznaka ATC- vet:
Purified Saponin, Cholesterol, Phosphatidylcholine, traces of Formaldehyde
Prečiščeni saponin, holesterol, fosfatidilholin, sledi formaldehida
Do not mix with any other vaccine or immunological product.
Ne mešajte z drugimi cepivi ali imunološkimi pripravki.
Cardboard box with 10 glass vials of 1 ml.
Zloženka z 10 steklenimi vialami po 1 ml.
Cardboard box with 10 pre-filled syringes with needles.
Zloženka z 10 napolnjenimi brizgami z iglami.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
Wim de Körverstraat 35 NL-5831 AN Boxmeer
Wim de Körverstraat 35 NL- 5831 AN Boxmeer Nizozemska
5/ 16 ANNEX II
5/ 17 DODATEK II
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
76 35 041 Marburg Germany
76 35 041 Marburg Nemčija
CONDITIONS
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
OF
Izdaja zdravila je le na veterinarski recept.
MARKETING
PREPOVED PRODAJE, OSKRBE IN/ ALI UPORABE
AUTHORISATION
Navedba ni smiselna.
RESTRICTIONS REGARDING SUPPLY AND USE
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN ZAOSTANKOV ZDRAVILA (MRL)
Veterinary medicinal product subject to prescription.
Zdravilna učinkovina je učinkovina biološkega izvora, namenjena za vzbujanje aktivne imunosti, in ni zajeta v Uredbi Sveta (EGS) 2377/ 90.
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Status pomožnih snovi glede na MRL:
D.
Snov
The active substance being a principle of biological origin intended to produce active immunity is not in the scope of Council Regulation (EEC) 2377/ 90.
Status glede na MRL Dodatek II za vse živali, namenjene
The MRL status of the excipients is as follows:
Opombe
Magnesium chloride (MgCl2) Calcium chloride (CaCl2)
Dodatek II za vse živali, namenjene za proizvodnjo živil
7/ 16 ANNEX III
7/ 17 DODATEK III
9/ 16 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
9/ 17 PODATKI NA ZUNANJI OVOJNINI
Tetanus toxoid 40 Lf/ ml
Toksoid tetanusa 40 Lf/ ml
Active immunisation of horses against tetanus.
Aktivna imunizacija konj proti tetanusu.
Read package leaflet before use (Comment:
Pred uporabo preberite navodilo za uporabo.
Statement will be printed only once on the package item)
(Navedba bo na pakiranju tiskana samo enkrat.)
THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
BESEDILO “ SAMO ZA ŽIVALI ” IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, če je navedba smiselna
For animal treatment only-To be supplied only on veterinary prescription
Samo za živali - oskrba le na podlagi veterinarskega recepta.
THE WORDS "KEEP OUT OF REACH AND SIGHT OF CHILDREN"
BESEDILO “ ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM ”
11/ 16 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
11/ 17 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES
KOLIČINA ZDRAVILNE( IH) UČINKOVIN( E)
13/ 16 PACKAGE LEAFLET FOR Equilis Te, suspension for injection, for horses
13/ 17 NAVODILO ZA UPORABO Equilis Te, suspenzija za injiciranje za konje
Active substance Tetanus toxoid
Zdravilna učinkovina
40 Lf2
40 Lf2 Toksoid tetanusa
2 Flocculation equivalents; corresponds with ≥ 30 IU/ ml guinea pig serum in the Ph. Eur. potency test
Eur.
14/ 16 7.
14/ 17 Občasno je možna bolečina na mestu dajanja.
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT( I) IN NAČIN UPORABE ZDRAVILA
V4 42 months
42
Concurrent use of Equilis Te and Tetanus-Serum from Intervet may reduce active immunity against tetanus compared to horses vaccinated with Equilis Te in the absence of tetanus antitoxin serum.
Sočasna uporaba Equilisa Te in Intervetovega Tetanus - Seruma lahko zmanjša aktivno imunost proti tetanusu v primerjavi s konji, cepljenimi z Equilisom Te, ki niso prejeli seruma z antitoksinom tetanusa.
Allow the vaccine to reach a temperature of 15°C - 25°C.
Cepivo pred uporabo ogrejte na sobno temperaturo 15 °C – 25 °C.
Administer 1 ml of vaccine i. m..
15/ 17 Vbrizgajte 1 ml cepiva i. m.
Safety and efficacy of concurrent use with Tetanus-Serum from Intervet has been demonstrated.
Dokazani sta varnost in učinkovitost sočasne uporabe z Intervetovim Tetanus- Serumom.
Do not freeze.
Ne Zdravilo ne sme zmrzniti.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other.
O varnosti in učinkovitosti sočasne uporabe cepiva z drugimi cepivi ni podatkov.
For any information about this veterinary product, please contact the local representative of the marketing authorisation holder.
16/ 17 Za vse nadaljnje informacije o tem zdravilu se obrnite na krajevno predstavništvo imetnika dovoljenja za promet z zdravilom.
EQUIOXX contains the active substance firocoxib in an oral paste for horses (8.2 mg/ g).
Zdravilo EQUIOXX vsebuje zdravilno učinkovino firokoksib v peroralni pasti za konje (8, 2 mg/ g).
The dose is 0.1 mg firocoxib per kg bodyweight, given once a day.
Odmerek je 0, 1 mg firokoksiba na kilogram telesne mase enkrat na dan.
EQUIOXX is presented as a paste with a special syringe that allows the right amount of medicine to be drawn and given directly into the horse’ s mouth.
Zdravilo EQUIOXX je v obliki paste na voljo skupaj s posebno brizgo, s pomočjo katere se odmeri in konju neposredno v gobec vbrizga ravno prava količina zdravila.
The duration of treatment will depend on the horse’ s response, but should not exceed 14 days.
Trajanje zdravljenja je odvisno od odziva konja, vendar ne sme trajati dlje kot 14 dni.
The active substance in EQUIOXX, firocoxib, is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group of medicines called ‘ cyclo-oxygenase-2 (COX-2) inhibitors’ (or Coxibs).
Zdravilna učinkovina v zdravilu EQUIOXX, firokoksib, je nesteroidno protivnetno zdravilo (NSAID), ki spada v skupino zdravil, imenovanih inhibitorji ciklooksigenaze- 2 (COX- 2) (oziroma koksibi).
It blocks the COX-2 enzyme, resulting in a reduction in the production of prostaglandins, substances that are involved in the inflammation process.
Z zaviranjem encima COX- 2 koksib povzroči zmanjšanje nastajanja prostaglandinov, snovi, ki sodelujejo pri vnetnem procesu.
EQUIOXX has been studied in laboratory animals, as well as in horses that were treated in various veterinary practices/ clinics across Europe (“ clinical studies”).
Zdravilo EQUIOXX so raziskovali pri laboratorijskih živalih, kot tudi pri konjih, ki so jih zdravili v različnih veterinarskih ambulantah in klinikah po vsej Evropi (klinične študije).
The studies looked at the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
V študijah so preučevali učinkovitost 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. effectiveness of the medicine in improving lameness, pain on manipulation/ palpation, joint swelling and ability to move.
Reproduction is authorised provided the source is acknowledged. zdravila pri izboljševanju šepavosti, lajšanju bolečine pri ravnanju/ otipavanju, otekanju sklepov in zmožnosti premikanja.
EQUIOXX oral paste administered once daily for 14 days at a dose of 0.1 mg/ kg improved clinical scores for lameness and soft tissue injuries in horses and also helped relieve pain and inflammation associated with osteoarthritis in horses.
Zdravilo EQUIOXX v obliki peroralne paste enkrat dnevno v času 14 dni in pri odmerku 0, 1 mg/ kg je pri konjih izboljšalo klinične ocene šepavosti in poškodb mehkih tkiv ter pomagalo lajšati bolečine in vnetja, povezana z osteoartritisom.
The side effects of EQUIOXX are typical for those seen with other medicines in this class (NSAIDs) such as oral lesions (tissue damage) in the mouth of horses, soft faeces/ diarrhoea or lethargy (unresponsiveness).
Neželeni učinki zdravila EQUIOXX, kot so oralne lezije (vrsta poškodb tkiva) v ustni votlini konj, mehko blato ali driska in letargija (neodzivanje), so značilni za vsa zdravila iz tega razreda zdravil (NSAID).
The European Commission granted the marketing authorisation valid throughout the European Union, for EQUIOXX to Merial on 25/ 06/ 2008.
Evropska komisija je dovoljenje za promet z zdravilom EQUIOXX, veljavno po vsej Evropski uniji, odobrila družbi Merail dne 25. 06. 2008.
This summary was last updated in June 2008.
Povzetek je bil nazadnje posodobljen 06- 2008.
Oral paste
peroralna pasta
Pre-filled syringe (PP)
Brizga za peroralno dajanje
7.32 g
7, 32 g paste
26 days
26 dni
QUALITATIVE AND QUANTITATIVE COMPOSITION
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Each syringe contains 7.32 g of paste and delivers:
EQUIOXX 8. 2 mg/ g peroralna pasta za konje
PHARMACEUTICAL FORM
Vsaka brizga za peroralno dajanje s po 7, 32 g paste in nosilca vsebuje:
Oral paste.
firokoksib 8, 2 mg/ g
White to off-white paste.
Za celoten seznam pomožnih snovi glejte oddelek 6. 1
4.1 Target species
Peroralna pasta.
Horses.
KLINIČNI PODATKI
4.2 Indications for use specifying the target species
4. 1 Ciljne živalske vrste
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
4. 2 Indikacije za uporabo pri ciljnih živalskih vrstah
Do not use in animals suffering from gastrointestinal disorders and haemorrhage, impaired hepatic, cardiac or renal function and bleeding disorders.
Ne uporabljajte pri živalih, ki imajo oslabljeno jetrno, srčno ter ledvično funkcijo ter motnje v strjevanju krvi.
Do not use concomitantly with corticosteroids or other NSAIDs.
Ne uporabljajte sočasno s kortikosteroidi ali drugimi nesteroidnimi priotivnetnimi zdravili (NSAID).
2/ 17 Special precautions to be taken by the person administering the veterinary medicinal product to animals
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
Avoid contact with eyes and skin.
2/ 16 Izogibajte se stiku z očmi in kožo.
Lesions (erosion/ ulceration) of the oral mucosa and of the skin around the mouth may occasionally be observed in treated animals.
Pri zdravljenih živalih se občasno pojavijo poškodbe (erozije / ulkusi) na ustni sluznici in na koži okrog ust.
Concomitant treatment with molecules displaying action on renal flow (e. g. diuretics) should be subject to clinical monitoring.
Pri sočasnem zdravljenju z učinkovinami, ki vplivajo na delovanje ledvic (npr. diuretiki), je potrebno nadzorovati delovanje le- teh.
Administer 0.1 mg firocoxib per kg bodyweight, once daily.
Enkrat dnevno dajte 0, 1 mg/ kg telesne mase firokoksiba.
To administer EQUIOXX at the dose of 0.1 mg firocoxib/ kg, set the syringe plunger to the appropriate dose division for the horse’ s weight.
Za aplikacijo zdravila EQUIOXX v odmerku 0, 1 mg firokoksiba/ kg telesne mase, nastavite bat brizge na primeren razdelek odmerka, glede na telesno maso konja.
To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid overdosing.
Za določitev pravega odmerka in da se izognemo prevelikemu odmerjanju, naj bo telesna masa živali čim bolj natančno določena,
To deliver firocoxib at the appropriate dosage, unlock the knurled ring on the syringe plunger by rotating it ¼ turn and slide it along the plunger shaft to the appropriate dose division for the horse’ s weight.
Primerni odmerek firokoksiba nastavite z obročem na batu brizge tako, da ga zavrtite za ¼ kroga in ga potegnete vzdolž osi bata do primernega razdelka, glede na telesno maso konja.
Rotate the plunger ring ¼ turn to lock it in place and ensure it is locked.
Obroč zavrtite in pritrdite na batu z zavojem za ¼, ter se prepričajte, da je pravilno nameščen.
Make sure the horse’ s mouth contains no feed.
Prepričajte se, da konj v ustih nima krme.
Insert the syringe tip into the horse’ s mouth at the interdental space and deposit the paste on the base of the tongue.
Konico brizge vtaknite konju v medzobni prostor v ustih in stisnite pasto na bazo jezika.
3/ 17 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
4. 10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno)
Lesions (erosion/ ulceration) of the oral mucosa and of the skin around the mouth may occasionally be observed in treated animals when administered the recommended treatment dose.
Pri živalih, zdravljenih s priporočenimi odmerki zdravila, se občasno pojavijo poškodbe (erozije / ulkusi) na ustni sluznici in na koži okrog ust.
The incidence of oral/ skin lesions increases with increasing dose.
Poškodbe kože in sluznice so z zvišanjem odmerkov pogostejše.
At high dosages and prolonged treatment (3 times the recommended dose for 42 consecutive days and 2.5 times the recommended dose for 92 consecutive days administered once daily) mild to moderate renal lesions were observed.
3/ 16 V velikih odmerkih in pri podaljšanem zdravljenju (3- kratni priporočeni odmerek 42 zaporednih dni in 2, 5- kratni priporočeni odmerek 92 zaporednih dni enkrat dnevno), so opazili blage do zmerne poškodbe ledvic.
26 days Do not use in mares producing milk for human consumption.
26 dni Ni dovoljena uporaba pri živalih v laktaciji, katerih mleko je namenjeno prehrani ljudi.
Anti-inflammatory and anti-rheumatic products, non-steroids, ATC vet code:
Farmakoterapevtska skupina: protivnetna zdravila in zdravila proti revmi, nesteroidna zdravila, Veterinarska koda ATC:
Firocoxib is a non-steroidal anti-inflammatory drug (NSAID) belonging to the Coxib group, which acts by selective inhibition of cyclooxygenase-2 (COX-2)-mediated prostaglandin synthesis.
Firokoksib je nesteroidno protivnetno zdravilo, ki spada v skupino koksibov in deluje po mehanizmu selektivne inhibcije sinteze prostaglandinov, ki jo posreduje ciklooksigenaza- 2 (COX- 2).
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
COX- 2 je izoforma encima, za katerega se je izkazalo, da je induciran z dražljaji, ki delujejo v smeri nastanka vnetja, in za katerega se domneva, da je primarno odgovoren za sintezo prostanoidnih mediatorjev za bolečino, vnetje in vročino.
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception, and cognitive function). “ In “ in vitro” equine whole blood assays, firocoxib exhibits 222 to 643 fold selectivity for COX-2 over COX-1.
Za COX- 2 se domneva tudi, da je vpleten v procesu ovulacije, implantacije, zaprtju duktusa ductus arteriosus in v funkcije osrednjega živčnega sistema (indukcija vročine, percepcija bolečine in kognitivne funkcije).